Akums Drugs Reports Modest Profit Rise, Strong Revenue Growth in Q3

• Akums Drugs and Pharmaceuticals Limited reported a 1.8% increase in net profit to ₹66.3 crore for Q3.
• Revenue surged by 14.8% year-on-year, reaching ₹1,159.5 crore.
• EBITDA climbed 21.3% to ₹147 crore, with the margin expanding to 12.7%.
• Improved operating performance and cost management contributed to margin expansion.
• Shares closed at ₹458.90 on NSE, down 1.10% for the day.